JP MORGAN/CALL/BOSTON SCIENTIFIC/84/0.1/17.01.25 | Delayed Börse Stuttgart 04:58:44 2024-07-17 am EDT | ||
| 0.57 EUR | -3.39% |
|
| 1 month | -10.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 0.57 | -3.39% |
| 24-07-16 | 0.59 | -6.35% |
| 24-07-15 | 0.63 | +23.53% |
| 24-07-12 | 0.51 | -7.27% |
| 24-07-11 | 0.55 | +7.84% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 04:58 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK9NJM |
| ISIN | DE000JK9NJM6 |
| Date issued | 2024-04-25 |
| Strike | 84 $ |
| Maturity | 2025-01-17 (184 Days) |
| Parity | 10 : 1 |
| Emission price | 0.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.67 € |
|---|---|
| Lowest since issue | 0.43 € |
| Spread | 0.05 € |
| Spread % | 8.20% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
77.41
USD
Average target price
84.1
USD
Spread / Average Target
+8.64%
- Stock Market
- Warrants
- Warrant
